Kenneth Booth Kurica, MD | |
5390 N Academy Blvd, Suite 300, Colorado Springs, CO 80918-4062 | |
(719) 596-6110 | |
(719) 596-6112 |
Full Name | Kenneth Booth Kurica |
---|---|
Gender | Male |
Speciality | Technician, Other |
Location | 5390 N Academy Blvd, Colorado Springs, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356326300 | NPI | - | NPPES |
01232586 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | 23258 (Colorado) | Secondary |
247200000X | Technician, Other | 23258 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kenneth Booth Kurica, MD 5390 N Academy Blvd, Suite 300, Colorado Springs, CO 80918-4062 Ph: (719) 596-6110 | Kenneth Booth Kurica, MD 5390 N Academy Blvd, Suite 300, Colorado Springs, CO 80918-4062 Ph: (719) 596-6110 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
While early research on the adaptive immune response to COVID-19 primarily looked at antibodies, more information is now emerging on how T cells react to the SARS-CoV-2 virus - addressing a crucial knowledge gap, say Daniel Altmann and Rosemary Boyton in a new Perspective.
Bracing often is recommended for adolescents diagnosed with idiopathic adolescent scoliosis, and a spinal curve between 25 and 45 degrees. When worn consistently and as directed, braces have been found to effectively halt or slow further progression of a spinal curve, often preventing surgery.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).
› Verified 4 days ago